胆管がん治療薬の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年から2032年までの予測

胆管がん治療薬の世界需要は、2023年の2億2,260万米ドルから2032年には4億1,513万米ドル近くの市場規模に達し、調査期間2024～2032年のCAGRは7.17%に達すると推定されます。

胆管がん治療薬は、胆管に発生するまれで攻撃的ながんである胆管がんを治療するために特別に設計された薬剤です。これらの薬剤は、胆管内のがん細胞を標的とし、その増殖を阻害することで効果を発揮します。治療の選択肢としては、腫瘍増殖における特定の分子標的を攻撃する標的療法や、急速に分裂するがん細胞を死滅させる化学療法薬があります。さらに、新しい免疫療法や併用療法も有効性を高めるために研究されています。薬剤の選択は、がんの病期、遺伝的特徴、患者の全身状態によって異なり、腫瘍の縮小、症状のコントロール、生存期間の延長を目指します。

市場力学

胆管がんの罹患率の増加と疾患に対する意識の高まりが、胆管がん治療薬の需要を促進しています。分子生物学とゲノミクスの進歩により、標的療法と個別化治療の選択肢が開発され、治療効果と患者の転帰が向上しています。免疫療法や新規ドラッグデリバリーシステムへの注目の高まりは、胆管がん治療薬市場に新たな機会をもたらしています。さらに、新薬候補や併用療法を模索する調査や臨床試験の増加が、このセグメントの技術革新を加速させています。医療インフラが整備され、がん研究への投資が増加している新興市場は、さらなる成長の展望をもたらしています。画期的な治療法の開発に投資し、研究機関や医療プロバイダーとの戦略的パートナーシップを確立している企業は、市場シェアを獲得し、胆管がん治療薬におけるアンメットニーズに対応する上で有利な立場にあります。しかし、先進的ながん治療薬のコストが高いことが、胆管がん治療薬市場の妨げになる可能性があります。

調査レポートは、ポーターのファイブフォースモデル、市場の魅力分析、バリューチェーン分析を取り上げています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは、胆管がん治療薬の世界市場における各セグメントを包括的に評価することもできます。胆管がん治療薬業界の成長と動向は、この調査への全体的なアプローチを記載しています。

市場セグメンテーション

胆管がん治療薬市場レポートでは、国別と地域別のセグメントに関する詳細なデータを提供することで、戦略担当者が各製品またはサービスの対象層を特定し、今後のビジネス機会に役立てることができます。

地域分析

このセクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカにおける胆管がん治療薬市場の現在と将来の需要を強調する地域展望をカバーしています。さらに、本レポートでは、すべての主要地域における個々の用途セグメントの需要、推定・予測に焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

• 市場のハイライト
• 世界市場スナップショット

第3章 胆管がん治療薬-産業分析

• イントロダクション-市場力学
• 市場促進要因
• 市場抑制要因
• 市場機会
• 業界動向
• ポーターのファイブフォース分析
• 市場の魅力分析

第4章 バリューチェーン分析

• バリューチェーン分析
• 原材料分析
  • 原材料リスト
  • 原材料メーカー一覧
  • 主要原材料の価格動向
• 潜在的バイヤー一覧
• マーケティングチャネル
  • 直接マーケティング
  • 間接マーケティング
  • マーケティングチャネル発展動向

第5章 胆管がん治療薬の世界市場分析：製品別

• 製品別概要
• 製品別過去・予測データ分析
• 5-フルオロウラシル（5-FU）
• ゲムシタビン
• シスプラチン
• カペシタビン
• オキサリプラチン
• その他

第6章 胆管がん治療薬の世界市場分析：用途別

• 用途別概要
• 用途別過去・予測データ分析
• 病院
• クリニック
• その他

第7章 胆管がん治療薬の世界市場分析：地域別

• 地域別展望
• イントロダクション
• 北米売上分析
  • 概要、実績と予測
  • 北米：セグメント別
  • 北米：国別
  • 米国
  • カナダ
  • メキシコ
• 欧州売上分析
  • 概要、実績と予測
  • 欧州：セグメント別
  • 欧州：国別
  • 英国
  • フランス
  • ドイツ
  • イタリア
  • ロシア
  • その他の欧州
• アジア太平洋売上分析
  • 概要、実績と予測
  • アジア太平洋：セグメント別
  • アジア太平洋：国別
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア
  • 東南アジア
  • その他のアジア太平洋
• ラテンアメリカ売上分析
  • 概要、実績と予測
  • ラテンアメリカ：セグメント別
  • ラテンアメリカ：国別
  • ブラジル
  • アルゼンチン
  • ペルー
  • チリ
  • その他のラテンアメリカ
• 中東・アフリカ売上分析
  • 概要、実績と予測
  • 中東・アフリカ：セグメント別
  • 中東・アフリカ：国別一覧
  • サウジアラビア
  • アラブ首長国連邦
  • イスラエル
  • 南アフリカ
  • その他の中東・アフリカ

第8章 胆管がん治療薬企業の競合情勢

• 胆管がん治療薬の市場競争
• 提携・協力・契約
• 合併・買収
• 新製品の上市
• その他の開発

第9章 企業プロファイル

• 上位企業の市場シェア分析
• 市場集中度
• Delcath Systems Inc.
• Accord Healthcare
• F. Hoffmann-La Roche Ltd.
• Teva Pharmaceutical Industries Ltd.
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Eli Lilly And Company
• Mylan N.V
• Fresenius Kabi AG
• Intercept Pharmaceuticals Inc.
• Celgene Corporation

LIST OF TABLES

• Market Snapshot
• Drivers: Impact Analysis
• Restraints: Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• Analysis By Product (USD MN)
• 5-fluorouracil (5-FU) Market Sales By Geography (USD MN)
• Gemcitabine Market Sales By Geography (USD MN)
• Cisplatin Market Sales By Geography (USD MN)
• Capecitabine Market Sales By Geography (USD MN)
• Oxaliplatin Market Sales By Geography (USD MN)
• Others Market Sales By Geography (USD MN)
• Analysis By Application (USD MN)
• Hospitals Market Sales By Geography (USD MN)
• Clinics Market Sales By Geography (USD MN)
• Others Market Sales By Geography (USD MN)
• Global Bile Duct Cancer Drug Market Sales By Geography (USD MN)
• North America Market Analysis (USD MN)
• United States Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate By Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Bile Duct Cancer Drug Report
• Market Research Process
• Market Research Methodology
• Global Bile Duct Cancer Drug Market Size, By Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis By Product
• Market Attractiveness Analysis By Application
• Market Attractiveness Analysis By Region
• Value Chain Analysis
• Global Market Analysis By Product (USD MN)
• 5-fluorouracil (5-FU) Market Sales By Geography (USD MN)
• Gemcitabine Market Sales By Geography (USD MN)
• Cisplatin Market Sales By Geography (USD MN)
• Capecitabine Market Sales By Geography (USD MN)
• Oxaliplatin Market Sales By Geography (USD MN)
• Others Market Sales By Geography (USD MN)
• Global Market Analysis By Application (USD MN)
• Hospitals Market Sales By Geography (USD MN)
• Clinics Market Sales By Geography (USD MN)
• Others Market Sales By Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

The global demand for Bile Duct Cancer Drug Market is presumed to reach the market size of nearly USD 415.13 Million by 2032 from USD 222.6 Million in 2023 with a CAGR of 7.17% under the study period 2024-2032.

Bile duct cancer drugs are medications specifically designed to treat cholangiocarcinoma, a rare and aggressive cancer that originates in the bile ducts. These drugs work by targeting & inhibiting the growth of cancer cells within the bile ducts. Treatment options include targeted therapies that attack specific molecular targets in tumor growth and chemotherapy drugs that kill rapidly dividing cancer cells. Additionally, newer immunotherapies and combination therapies are being explored to improve efficacy. The choice of drug depends on the cancer's stage, genetic characteristics, and the patient's overall health, aiming to reduce tumor size, control symptoms, and extend survival.

Market Dynamics

The increasing incidence of cholangiocarcinoma and the rising awareness of the disease are fueling the demand for bile duct cancer drugs. Advances in molecular biology & genomics have led to the development of targeted therapies and personalized treatment options, enhancing treatment efficacy and patient outcomes. The growing focus on immunotherapy and novel drug delivery systems presents new opportunities for the bile duct cancer drug market. Additionally, the rise in research and clinical trials exploring new drug candidates and combination therapies is accelerating innovation in this field. Emerging markets with growing healthcare infrastructure and increasing investment in cancer research offer further growth prospects. Companies that invest in developing breakthrough therapies and establishing strategic partnerships with research institutions and healthcare providers are well-positioned to capture market share and address the unmet needs in bile duct cancer treatment. However, the high cost of advanced cancer therapies may hinder the bile duct cancer drug market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Bile Duct Cancer Drug. The growth and trends of Bile Duct Cancer Drug industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Bile Duct Cancer Drug market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

• 5-fluorouracil (5-FU)
• Gemcitabine
• Cisplatin
• Capecitabine
• Oxaliplatin
• Others

By Application

• Hospitals
• Clinics
• Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Bile Duct Cancer Drug market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Bile Duct Cancer Drug market include Delcath Systems Inc., Accord Healthcare, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Pfizer Inc., Eli Lilly And Company, Mylan N.V, Fresenius Kabi AG, Intercept Pharmaceuticals Inc., Celgene Corporation, Among Others. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. BILE DUCT CANCER DRUG - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Product
  • 3.7.2 Market Attractiveness Analysis By Application
  • 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL BILE DUCT CANCER DRUG MARKET ANALYSIS BY PRODUCT

• 5.1. Overview By Product
• 5.2. Historical and Forecast Data Analysis By Product
• 5.3. 5-fluorouracil (5-FU) Historic and Forecast Sales By Regions
• 5.4. Gemcitabine Historic and Forecast Sales By Regions
• 5.5. Cisplatin Historic and Forecast Sales By Regions
• 5.6. Capecitabine Historic and Forecast Sales By Regions
• 5.7. Oxaliplatin Historic and Forecast Sales By Regions
• 5.8. Others Historic and Forecast Sales By Regions

6. GLOBAL BILE DUCT CANCER DRUG MARKET ANALYSIS BY APPLICATION

• 6.1. Overview By Application
• 6.2. Historical and Forecast Data Analysis By Application
• 6.3. Hospitals Historic and Forecast Sales By Regions
• 6.4. Clinics Historic and Forecast Sales By Regions
• 6.5. Others Historic and Forecast Sales By Regions

7. GLOBAL BILE DUCT CANCER DRUG MARKET ANALYSIS BY GEOGRAPHY

• 7.1. Regional Outlook
• 7.2. Introduction
• 7.3. North America Sales Analysis
  • 7.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.3.2 North America By Segment Sales Analysis
  • 7.3.3 North America By Country Sales Analysis
  • 7.3.4 United States Sales Analysis
  • 7.3.5 Canada Sales Analysis
  • 7.3.6 Mexico Sales Analysis
• 7.4. Europe Sales Analysis
  • 7.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.4.2 Europe By Segment Sales Analysis
  • 7.4.3 Europe By Country Sales Analysis
  • 7.4.4 United Kingdom Sales Analysis
  • 7.4.5 France Sales Analysis
  • 7.4.6 Germany Sales Analysis
  • 7.4.7 Italy Sales Analysis
  • 7.4.8 Russia Sales Analysis
  • 7.4.9 Rest Of Europe Sales Analysis
• 7.5. Asia Pacific Sales Analysis
  • 7.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.5.2 Asia Pacific By Segment Sales Analysis
  • 7.5.3 Asia Pacific By Country Sales Analysis
  • 7.5.4 China Sales Analysis
  • 7.5.5 India Sales Analysis
  • 7.5.6 Japan Sales Analysis
  • 7.5.7 South Korea Sales Analysis
  • 7.5.8 Australia Sales Analysis
  • 7.5.9 South East Asia Sales Analysis
  • 7.5.10 Rest Of Asia Pacific Sales Analysis
• 7.6. Latin America Sales Analysis
  • 7.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.6.2 Latin America By Segment Sales Analysis
  • 7.6.3 Latin America By Country Sales Analysis
  • 7.6.4 Brazil Sales Analysis
  • 7.6.5 Argentina Sales Analysis
  • 7.6.6 Peru Sales Analysis
  • 7.6.7 Chile Sales Analysis
  • 7.6.8 Rest of Latin America Sales Analysis
• 7.7. Middle East & Africa Sales Analysis
  • 7.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.7.2 Middle East & Africa By Segment Sales Analysis
  • 7.7.3 Middle East & Africa By Country Sales Analysis
  • 7.7.4 Saudi Arabia Sales Analysis
  • 7.7.5 UAE Sales Analysis
  • 7.7.6 Israel Sales Analysis
  • 7.7.7 South Africa Sales Analysis
  • 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE BILE DUCT CANCER DRUG COMPANIES

• 8.1. Bile Duct Cancer Drug Market Competition
• 8.2. Partnership/Collaboration/Agreement
• 8.3. Merger And Acquisitions
• 8.4. New Product Launch
• 8.5. Other Developments

9. COMPANY PROFILES OF BILE DUCT CANCER DRUG INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Market Concentration Rate
• 9.3. Delcath Systems Inc.
  • 9.3.1 Company Overview
  • 9.3.2 Company Revenue
  • 9.3.3 Products
  • 9.3.4 Recent Developments
• 9.4. Accord Healthcare
  • 9.4.1 Company Overview
  • 9.4.2 Company Revenue
  • 9.4.3 Products
  • 9.4.4 Recent Developments
• 9.5. F. Hoffmann-La Roche Ltd.
  • 9.5.1 Company Overview
  • 9.5.2 Company Revenue
  • 9.5.3 Products
  • 9.5.4 Recent Developments
• 9.6. Teva Pharmaceutical Industries Ltd.
  • 9.6.1 Company Overview
  • 9.6.2 Company Revenue
  • 9.6.3 Products
  • 9.6.4 Recent Developments
• 9.7. Bristol-Myers Squibb Company
  • 9.7.1 Company Overview
  • 9.7.2 Company Revenue
  • 9.7.3 Products
  • 9.7.4 Recent Developments
• 9.8. Pfizer Inc.
  • 9.8.1 Company Overview
  • 9.8.2 Company Revenue
  • 9.8.3 Products
  • 9.8.4 Recent Developments
• 9.9. Eli Lilly And Company
  • 9.9.1 Company Overview
  • 9.9.2 Company Revenue
  • 9.9.3 Products
  • 9.9.4 Recent Developments
• 9.10. Mylan N.V
  • 9.10.1 Company Overview
  • 9.10.2 Company Revenue
  • 9.10.3 Products
  • 9.10.4 Recent Developments
• 9.11. Fresenius Kabi AG
  • 9.11.1 Company Overview
  • 9.11.2 Company Revenue
  • 9.11.3 Products
  • 9.11.4 Recent Developments
• 9.12. Intercept Pharmaceuticals Inc.
  • 9.12.1 Company Overview
  • 9.12.2 Company Revenue
  • 9.12.3 Products
  • 9.12.4 Recent Developments
• 9.13. Celgene Corporation
  • 9.13.1 Company Overview
  • 9.13.2 Company Revenue
  • 9.13.3 Products
  • 9.13.4 Recent Developments
• 9.14. Others
  • 9.14.1 Company Overview
  • 9.14.2 Company Revenue
  • 9.14.3 Products
  • 9.14.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies